Lantern Pharma up on FDA nod to begin early-stage study on cancer therapy

Lantern Pharma

12/06/2023 14:19

** Lantern Pharma Inc's shares  LTRN.O  rise 2.2% to $5.52
premarket
    ** AI firm focused on cancer said the U.S. FDA has granted
the co clearance to initiate study of its therapy to treat solid
tumors and central nervous system (CNS) cancers 
    ** The early-stage study for therapy, developed using the
company's AI and machine learning platform, is anticipated to
begin during the current quarter
    ** Co said the study is expected to be completed by the
first half of 2024
    ** Up to Friday's close, stock had fallen ~11% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))